On this page · 5 sections→
Where the EU money came from
Funding by EU programme. Amounts are Accession Therapeutics Limited's own share of each project, not the project's full budget.
- Horizon Europe€5.0M · 2 projects
Projects
2 EU-funded projects, newest first. Accession Therapeutics Limited led 1 of them as coordinator. Each links to the official record.
- TAISTCoordinator
TUMOUR ACTIVATED IMMUNOTHERAPY FOR SOLID TUMOURS (TAIST)
Horizon Europe · 2026–2029 · Project on CORDIS ↗
€5.0Mtheir share - INVECTAAssociated partner
Integrative characterisation of Novel adenovirus VECtors aimed at Therapeutic Applications
Horizon Europe · 2023–2027 · Project on CORDIS ↗
Works most with
Organisations that shared the most EU projects with this one. A good starting list for consortium partners.
- Agencia Estatal Consejo Superior de Investigaciones CientificasSpain · 1 shared project
- Universiteit UtrechtNetherlands · 1 shared project
- Cardiff UniversityUnited Kingdom · 1 shared project
- Universidad Autonoma de MadridSpain · 1 shared project
- Ruder Boskovic InstituteCroatia · 1 shared project
- BioAgilytix Europe GmbHGermany · 1 shared project
- Colibri Scientific LimitedUnited Kingdom · 1 shared project
- Histologix LimitedUnited Kingdom · 1 shared project
- CellCarta NVBelgium · 1 shared project
Fields it works in
Research fields recorded on its Horizon projects.
- biophysics
- immunology
- immunotherapy
- lung cancer
- mortality
- oncology
- structural biology
- virology
Is this your organisation?
Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.
Claim this profile →Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships.